GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » Short-Term Debt & Capital Lease Obligation

Oragenics (Oragenics) Short-Term Debt & Capital Lease Obligation : $0.13 Mil (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Oragenics Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Oragenics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.13 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Oragenics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.


Oragenics Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Oragenics's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics Short-Term Debt & Capital Lease Obligation Chart

Oragenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.41 0.50 0.47 0.32

Oragenics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.19 0.52 0.32 0.13

Oragenics Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Oragenics Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Oragenics's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Oragenics (Oragenics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » Short-Term Debt & Capital Lease Obligation
Traded in Other Exchanges
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL, USA, 33634
Oragenics Inc is engaged in research and the development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its product (NT-CoV2-1) is an intranasal vaccine candidate to prevent coronavirus disease ("COVID-19") from the SARS-CoV-2 virus and variants thereof. Its focus on developing vaccines and novel antibiotics It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.
Executives
Fred Telling director 501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119
John P Gandolfo director 62 TERRACE ROAD, WAYNE NJ 07470
Cassidy Bruce A. Sr. director C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203
Janet Huffman officer: CFO, Secretary and Treasurer 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Robert C Koski director, 10 percent owner 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Michael O'keefe Sullivan officer: CFO, Secretary and Treasurer 3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607
Joseph Hernandez 10 percent owner C/O MICROLIN BIO, INC., NEW YORK NY 10022
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Koski Family Lp 10 percent owner 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Alan Joslyn director, officer: CEO and President 39 OLD RIDGEBURY ROAD, DANBURY CT 06810
Charles L Pope director 4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Christine L Koski director, 10 percent owner 1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243
Beverly Koski 10 percent owner
Thomas L Koski 10 percent owner

Oragenics (Oragenics) Headlines

From GuruFocus